Wechselwirkungen von Methylthioniniumchlorid (Methylenblau)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result. (Fachinformation zu Amfepramon, Gegenanzeigen)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [ see Warnings and Precautions (5.7) , Drug Interactions (7.1) ]. (Fachinformation zu Amfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (Fachinformation zu Amfetamin und Dexamfetamin, Gegenanzeigen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

CONTRAINDICATIONS IOPIDINE 1% Ophthalmic Solution is contraindicated for patients receiving monoamine oxidase inhibitor therapy and for patients with hypersensitivity to any component of this medication or to clonidine. (Fachinformation zu Apraclonidin, Gegenanzeigen)

Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids. [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 )]. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. (Fachinformation zu Benzfetamin, Gegenanzeigen)

Opioids and dextromethorphan may increase the risk of developing serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Avoid concomitant use of PROVAYBLUE with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan… (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

…including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Concomitant use of monoamine oxidase inhibitors (MAOIs). (Fachinformation zu Carbamazepin, Gegenanzeigen)

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with levodopa or carbidopa-levodopa combination products with or without carbidopa. (Fachinformation zu Carbidopa, Gegenanzeigen)

DUOPA is contraindicated in patients who are currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. (Fachinformation zu Carbidopa und Levodopa, Gegenanzeigen)

Carbidopa, levodopa and entacapone tablets is contraindicated in patients: Taking nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine). (Fachinformation zu Carbidopa, Levodopa und Entacapon, Gegenanzeigen)

…because deaths have been reported in this age group [see Warnings and Precautions (5.1)]. patients who are hypersensitive to carbinoxamine maleate or any of the inactive ingredients in Carbinoxamine Maleate Extended-Release Oral Suspension [see Warnings and Precautions (5.4)]. patients who are taking monoamine oxidase inhibitors (MAOI) [see Drug Interactions (7)]. (Fachinformation zu Carbinoxamin, Gegenanzeigen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitor therapy (See DRUG INTERACTIONS ). (Fachinformation zu Cyproheptadin, Gegenanzeigen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Taking monoamine oxidase inhibitors (MAOIs). (Fachinformation zu Deutetrabenazin, Gegenanzeigen)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Drug Interactions ]. (Fachinformation zu Dexamfetamin, Gegenanzeigen)

Antihistamines are also contraindicated in the following conditions: Hypersensitivity to dexchlorpheniramine maleate or other antihistamines of similar chemical structure Monoamine oxidase inhibitor therapy (See Drug Interaction section) (Fachinformation zu Dexchlorpheniramin, Gegenanzeigen)

• Concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises [see Drug Interactions ( 7.1 )] . (Fachinformation zu Dexmethylphenidat, Gegenanzeigen)

Opioids and dextromethorphan may increase the risk of developing serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Opioids and dextromethorphan may increase the risk of developing serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

Avoid use of diphenoxylate hydrochloride and atropine sulfate in patients who take MAOIs and monitor for signs and symptoms of hypertensive crisis (headache, hyperthermia, hypertension). (Fachinformation zu Diphenoxylat und Atropin, Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

…Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [ see Drug Interactions… (Fachinformation zu Doxylamin und Pyridoxin, Gegenanzeigen)

However, based on mechanism of action, the use of non-selective MAO inhibitors and linezolid should be avoided as there is a potential for increased blood pressure when taken with NORTHERA. (Fachinformation zu Droxidopa, Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Die Kombination von Johanniskraut mit Antidepressiva und anderen serotonergen Arzneimitteln erhöht das Risiko eines Serotoninsyndroms. (NCCIH, St. John's Wort)

INBRIJA is contraindicated in patients currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or who have recently (within 2 weeks) taken a nonselective MAO inhibitor. (Fachinformation zu Levodopa, Gegenanzeigen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

…including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan because of the potential for serious CNS reactions, including potentially fatal serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

Patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see Warnings and Precautions (5.7) and Drug Interactions (7.1) ] . (Fachinformation zu Lisdexamfetamin, Gegenanzeigen)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (Fachinformation zu Metaxalon, Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Fachinformation zu Methyldopa, Gegenanzeigen)

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ]. (Fachinformation zu Methylphenidat, Gegenanzeigen)

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, avoid use in patients with hypertension or in patients taking monoamine oxidase inhibitors [see Drug Interactions ( 7.1 )] . (Fachinformation zu Metoclopramid, Warnhinweise und Vorsichtsmaßnahmen)

Avoid use of MAO inhibitors or linezolid with midodrine. (Fachinformation zu Midodrin, Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Avoid concomitant use of PROVAYBLUE with medicinal products that enhance serotonergic transmission including antidepressants like SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin and norepinephrine reuptake inhibitors), MAOIs (monoamine oxidase inhibitors), bupropion, buspirone, clomipramine, mirtazapine, linezolid, opioids, and dextromethorphan… (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

…coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension, pulmonary hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other… (Fachinformation zu Phendimetrazin, Gegenanzeigen)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

…cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fachinformation zu Phentermin, Gegenanzeigen)

…Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release… (Fachinformation zu Phentermin und Topiramat, Gegenanzeigen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Opioids and dextromethorphan may increase the risk of developing serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (Fachinformation zu Pseudoephedrin, Warnhinweise)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

• Taking monoamine oxidase inhibitors (MAOIs). (Fachinformation zu Tetrabenazin, Gegenanzeigen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (Fachinformation zu Valbenazin, Arzneimittelwechselwirkungen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Avoid concomitant use of PROVAYBLUE with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs) and opioids. [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 )]. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

Clinically significant drug interactions with PROVAYBLUE are described below: The concomitant use of PROVAYBLUE with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Arzneimittelwechselwirkungen)

• Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs. (Fachinformation zu Ziprasidon, Gegenanzeigen)

WARNING: SEROTONIN SYNDROME WITH CONCOMITANT USE OF SEROTONERGIC DRUGS AND OPIOIDS PROVAYBLUE may cause serious or fatal serotonergic syndrome when used in combination with serotonergic drugs and opioids. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Boxed Warning (umrahmter Warnhinweis))

• Drugs that potentiate the effects of epinephrine include sympathomimetics, beta blockers, tricyclic antidepressants, MAO inhibitors, COMT inhibitors, clonidine, doxapram, oxytocin, levothyroxine sodium, and certain antihistamines. (Fachinformation zu Adrenalin, Arzneimittelwechselwirkungen)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (Fachinformation zu Arformoterol, Arzneimittelwechselwirkungen)

Monoamine Oxidase (MAO) Inhibitors Caution should be used when concomitantly administering MAO inhibitors and NUVIGIL. (Fachinformation zu Armodafinil, Arzneimittelwechselwirkungen)

The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants may produce severe, prolonged hypertension. (Fachinformation zu Articain und Adrenalin, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors may result in increased hypotension. (Fachinformation zu Brimonidin, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors may result in increased hypotension. (Fachinformation zu Brimonidin und Timolol, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Budesonid und Formoterol, Arzneimittelwechselwirkungen)

…of Adverse Reactions Due to Drug Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors… (Fachinformation zu Bupivacain, Warnhinweise und Vorsichtsmaßnahmen)

…of Adverse Reactions Due to Drug Interactions with MARCAINE WITH EPINEPHRINE Risk of Severe, Persistent Hypertension Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors… (Fachinformation zu Bupivacain und Adrenalin, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (Fachinformation zu Butalbital und Paracetamol, Arzneimittelwechselwirkungen)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (Fachinformation zu Butalbital, Acetylsalicylsäure und Koffein, Arzneimittelwechselwirkungen)

Drug Interactions The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. (Fachinformation zu Butalbital, Paracetamol und Koffein, Arzneimittelwechselwirkungen)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Fachinformation zu Carvedilol, Arzneimittelwechselwirkungen)

Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (Fachinformation zu Chloroprocain, Vorsichtsmaßnahmen)

Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines. (Fachinformation zu Clemastin, Arzneimittelwechselwirkungen)

…Interactions The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs. (Fachinformation zu Clonazepam, Arzneimittelwechselwirkungen)

…be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (Fachinformation zu Diazepam, Arzneimittelwechselwirkungen)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (Fachinformation zu Dicycloverin, Arzneimittelwechselwirkungen)

The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants. (Fachinformation zu Dikaliumclorazepat, Arzneimittelwechselwirkungen)

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines. (Fachinformation zu Diphenhydramin, Arzneimittelwechselwirkungen)

…1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance,… (Fachinformation zu Droperidol, Warnhinweise)

The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression. (Fachinformation zu Estazolam, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Fluticason und Salmeterol, Arzneimittelwechselwirkungen)

• MAO inhibitors, tricyclic antidepressants and drugs that prolong QTc interval may potentiate effect on the cardiovascular system. (Fachinformation zu Formoterol, Arzneimittelwechselwirkungen)

…Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

…increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, nonsteroidal anti-inflammatory… (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

Glipizide: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, some azoles, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

…Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor blood glucose… (Fachinformation zu Humaninsulin (Normalinsulin), Arzneimittelwechselwirkungen)

Drug Interactions MAO inhibitors should be used with caution in patients receiving hydralazine. (Fachinformation zu Hydralazin, Arzneimittelwechselwirkungen)

Consider methylene blue for treatment of encephalopathy. (Fachinformation zu Ifosfamid, Warnhinweise und Vorsichtsmaßnahmen)

Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Insulin aspart, Arzneimittelwechselwirkungen)

…Degludec Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (Fachinformation zu Insulin degludec, Arzneimittelwechselwirkungen)

…with LEVEMIR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (Fachinformation zu Insulin detemir, Arzneimittelwechselwirkungen)

…Glargine-yfgn Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors,… (Fachinformation zu Insulin glargin, Arzneimittelwechselwirkungen)

Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Insulin lispro, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants Ipratropium Bromide and Albuterol Sulfate Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the action of albuterol sulfate on the cardiovascular… (Fachinformation zu Ipratropiumbromid und Salbutamol, Arzneimittelwechselwirkungen)

Concomitant Use with MAO Inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (Fachinformation zu Isofluran, Arzneimittelwechselwirkungen)

Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (Fachinformation zu Isoprenalin, Arzneimittelwechselwirkungen)

Monoamine-oxidase inhibitors: Concomitant administration may potentiate the effects and toxicity of monoamine-oxidase inhibitors. (Fachinformation zu Kokain, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants : May potentiate effect of albuterol on the cardiovascular system. (Fachinformation zu Levosalbutamol, Arzneimittelwechselwirkungen)

Clinically Significant Drug Interactions The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. (Fachinformation zu Lidocain, Arzneimittelwechselwirkungen)

Risk of Adverse Reactions Due to Drug Interactions with FLAVALTA Risk of Severe, Persistent Hypertension Due to Drug Interactions Between FLAVALTA and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Administration of FLAVALTA (containing a vasoconstrictor, epinephrine) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants… (Fachinformation zu Lidocain und Adrenalin, Warnhinweise und Vorsichtsmaßnahmen)

Likewise, solutions of mepivacaine containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result. (Fachinformation zu Mepivacain, Warnhinweise)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (Fachinformation zu Metoprolol, Arzneimittelwechselwirkungen)

Catecholamine-depleting drugs (e.g., MAO inhibitors): Hypotension, bradycardia. (Fachinformation zu Metoprolol und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

Monoamine Oxidase (MAO) Inhibitors Caution should be used when concomitantly administering MAO inhibitors and PROVIGIL. (Fachinformation zu Modafinil, Arzneimittelwechselwirkungen)

…Nateglinide Drugs That May Increase the Blood-Glucose-Lowering Effect of Nateglinide and Susceptibility to Hypoglycemia Drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid,… (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines. (Fachinformation zu Oxymetazolin, Arzneimittelwechselwirkungen)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (Fachinformation zu Phenylephrin, Arzneimittelwechselwirkungen)

…steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, coumarins, probenecid and monoamine oxidase inhibitors. (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

…Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension. (Fachinformation zu Prilocain und Adrenalin, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors (MAOI) Drug interactions, including an increased incidence of extrapyramidal effects, have been reported when some MAOI and phenothiazines are used concomitantly. (Fachinformation zu Promethazin, Arzneimittelwechselwirkungen)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salbutamol, Arzneimittelwechselwirkungen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Salmeterol, Arzneimittelwechselwirkungen)

Non-selective MAO-inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures. (Fachinformation zu Sevofluran, Arzneimittelwechselwirkungen)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (Fachinformation zu Suxamethonium, Arzneimittelwechselwirkungen)

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants Terbutaline sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline sulfate on the vascular system may be potentiated. (Fachinformation zu Terbutalin, Vorsichtsmaßnahmen)

• Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (Fachinformation zu Umeclidiniumbromid und Vilanterol, Arzneimittelwechselwirkungen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Since the chemical structure of difenoxin hydrochloride is similar to meperidine hydrochloride, the concurrent use of MOTOFEN ® with monoamine oxidase inhibitors may, in theory, precipitate a hypertensive crisis. (Fachinformation zu Difenoxin und Atropin, Arzneimittelwechselwirkungen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

It is theoretically possible, therefore, that the combination of Entacapone Tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (Fachinformation zu Entacapon, Warnhinweise)

Clonidine, propofol, monoamine oxidase inhibitors (MAOIs), atropine C linical Impact: These drugs augment the pressor effect of ephedrine. (Fachinformation zu Ephedrin, Arzneimittelwechselwirkungen)

Examples: Nonsteroidal anti-inflammatory agents and other highly protein-boind drugs, salicylcates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta-adrenergic blocking agents; potentially with ciprofloxacin, micronazole. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. (Fachinformation zu Lidocain und Prilocain, Warnhinweise und Vorsichtsmaßnahmen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Antidepressants: The hypotensive effect of MAO inhibitors or tricyclic antidepressants may be exacerbated when administered with beta-blockers. (Fachinformation zu Propranolol, Arzneimittelwechselwirkungen)

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. (Fachinformation zu Ropivacain, Warnhinweise und Vorsichtsmaßnahmen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)

Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (Fachinformation zu Terbinafin, Arzneimittelwechselwirkungen)

It is theoretically possible, therefore, that the combination of Tolcapone tablets and a non-selective MAO inhibitor (e.g., phenelzine and tranylcypromine) would result in inhibition of the majority of the pathways responsible for normal catecholamine metabolism. (Fachinformation zu Tolcapon, Warnhinweise)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (Fachinformation zu Trihexyphenidyl, Arzneimittelwechselwirkungen)

Lack of Effectiveness Methemoglobinemia may not resolve or may rebound after response to treatment with PROVAYBLUE in patients with methemoglobinemia due to aryl amines such as aniline or sulfa drugs such as dapsone. (Fachinformation zu Methylthioniniumchlorid (Methylenblau), Warnhinweise und Vorsichtsmaßnahmen)